Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

about

Cerebral Amyloid Angiopathy: Similarity in African-Americans and Caucasians with Alzheimer's Disease.

P2860

Q54136792-671A8495-AC84-4368-869C-4DEDB953577E

P2860

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

Item

http://www.wikidata.org/entity/Q38758319

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

@en

type

Item

label

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

@en

prefLabel

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

@en

P1476

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

@en

P2093

Gary R Cutter

http://www.w3.org/2001/XMLSchema#string

Guoqiao Wang

http://www.w3.org/2001/XMLSchema#string

Lon S Schneider

http://www.w3.org/2001/XMLSchema#string

Richard E Kennedy

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

The Clinical Dementia Rating (CDR): current version and scoring rules

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.

Alzheimer's Disease Neuroimaging Initiative (ADNI): clinical characterization.

Community engagement in diverse populations for Alzheimer disease prevention trials.

Recruitment of a community-based cohort for research on diversity and risk of dementia.

Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials.

Vitamin E and donepezil for the treatment of mild cognitive impairment.

Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study.

P31

scholarly article

meta-analysis

P356

10.1016/J.JAGP.2017.04.013

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28554539

http://www.w3.org/2001/XMLSchema#string

P921

Alzheimer's disease

P932

5842064

http://www.w3.org/2001/XMLSchema#string

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

about

P2860

P2860

Challenging Assumptions About African American Participation in Alzheimer Disease Trials.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P31

P356

P577

P698

P921

P932